← Leaderboards
Rosa Lapalombella
Ohio State University
$5,349,017
Attributed
$10,798,303
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,798,303 · 5
By mechanism
R01$9,235,786 · 4
K12$1,562,517 · 1
Top collaborators
- John C Byrd10 shared
- Robert Alan Baiocchi5 shared
- Alice Scott Mims5 shared
- Deepa Sampath5 shared
- Jennifer A. Woyach5 shared
- Kristie A Blum2 shared
- William E. Carson2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Jennifer A. Woyach$6,733,332
- Alice Scott Mims$1,588,136
- Kerry Anne Rogers$1,321,382
- Deepa Sampath$2,215,864
- Sharyn D Baker$10,060,478
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalTargeted TreatmentTumorIn VivoChronic Lymphocytic LeukemiaS LymphomaClinical TrialsMutationEpigenetic ProcessDisease ProgressionGenesDiagnosisRelapseMouse ModelInhibitor/AntagonistMediatingNeoplastic CellLarge Cell Diffuse Non-Hodgkin&AposCombined Modality TherapyLymphomaPathway InteractionsPreventIn VitroPathogenesis
Grant awards (22)
OSU K12 Training Grant in Oncology$807,955
K12 · FY2025 · CA
OSU K12 Training Grant in Oncology$754,562
K12 · FY2024 · CA
Understanding Richter's Transformation in the targeted therapies era$450,684
R01 · FY2024 · CA · contact PI
Understanding Richter's Transformation in the targeted therapies era$464,916
R01 · FY2023 · CA · contact PI
Understanding Richter's Transformation in the targeted therapies era$464,916
R01 · FY2022 · CA · contact PI
Targeting NAMPT in Acute Myeloid Leukemia$461,498
R01 · FY2022 · CA · contact PI
Understanding Richter's Transformation in the targeted therapies era$474,404
R01 · FY2021 · CA · contact PI
Targeting NAMPT in Acute Myeloid Leukemia$470,916
R01 · FY2021 · CA · contact PI
Targeted Therapies for Richters Transformation$463,172
R01 · FY2021 · CA · contact PI
Understanding Richter's Transformation in the targeted therapies era$474,404
R01 · FY2020 · CA · contact PI
Targeting NAMPT in Acute Myeloid Leukemia$470,916
R01 · FY2020 · CA · contact PI
Targeted Therapies for Richters Transformation$463,172
R01 · FY2020 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$496,655
R01 · FY2019 · CA · contact PI
Targeting NAMPT in Acute Myeloid Leukemia$456,788
R01 · FY2019 · CA · contact PI
Targeted Therapies for Richters Transformation$449,278
R01 · FY2019 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$512,016
R01 · FY2018 · CA · contact PI
Targeting NAMPT in Acute Myeloid Leukemia$470,916
R01 · FY2018 · CA · contact PI
Targeted Therapies for Richters Transformation$461,935
R01 · FY2018 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$512,016
R01 · FY2017 · CA · contact PI
Targeted Therapies for Richters Transformation$452,551
R01 · FY2017 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$445,083
R01 · FY2016 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$319,550
R01 · FY2015 · CA · contact PI